Implementation of Pharmacogenetics to Individualize Treatment Regimens for Children with Acute Lymphoblastic Leukemia

References

• Evans WE, Crews KR, Pui CH. A health-care system perspective on implementing genomic medicine: pediatric acute lymphoblastic leukemia as a paradigm. Clin Pharmacol Ther. 2013;94(2):224–229.23462885
   PubMed Web of Science ®Google Scholar
• Stanulla M, Schrappe M, Yang S-K. Treatment of childhood acute lymphoblastic leukemia. Semin Hematol. 2009;46(1):52–63. doi:10.1053/j.seminhematol.2008.09.00719100368
   PubMed Web of Science ®Google Scholar
• Lopez-Lopez E, Gutierrez-Camino A, Bilbao-Aldaiturriaga N, Pombar-Gomez M, Martin-Guerrero I, Garcia-Orad A. Pharmacogenetics of childhood acute lymphoblastic leukemia. Pharmacogenomics. 2014;15(10):1383–1398. doi:10.2217/pgs.14.10625155938
   PubMed Web of Science ®Google Scholar
• Al-Mahayri ZN, Patrinos GP, Ali BR. Pharmacogenomics in pediatric acute lymphoblastic leukemia: promises and limitations. Pharmacogenomics. 2017;18(7):687–699. doi:10.2217/pgs-2017-000528468529
   PubMed Web of Science ®Google Scholar
• Lee SHR, Yang JJ. Pharmacogenomics in acute lymphoblastic leukemia. Best Pract Res Clin Haematol. 2017;30(3):229–236. doi:10.1016/j.beha.2017.07.00729050696
   PubMed Web of Science ®Google Scholar
• Mei L, Ontiveros EP, Griffiths EA, Thompson JE, Wang ES, Wetzler M. Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy. Blood Rev. 2015;29(4):243–249. doi:10.1016/j.blre.2015.01.00125614322
   PubMed Web of Science ®Google Scholar
• Rudin S, Marable M, Huang RS. The Promise of Pharmacogenomics in Reducing Toxicity During Acute Lymphoblastic Leukemia Maintenance Treatment. Genomics Proteomics Bioinformatics. 2017;15(2):82–93. doi:10.1016/j.gpb.2016.11.00328391009
   PubMed Web of Science ®Google Scholar
• Schmiegelow K, Nielsen SN, Frandsen TL, Nersting J. Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction. J Pediatr Hematol Oncol. 2014;36(7):503–517. doi:10.1097/MPH.000000000000020624936744
   PubMed Web of Science ®Google Scholar
• Davidsen ML, Dalhoff K, Schmiegelow K. Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2008;30(11):831–849. doi:10.1097/MPH.0b013e318186857018989161
   PubMed Web of Science ®Google Scholar
• Maxwell RR, Cole PD. Pharmacogenetic predictors of treatment-related toxicity among children with acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2017;12(3):176–186. doi:10.1007/s11899-017-0376-z28317081
   PubMed Web of Science ®Google Scholar
• Relling MV, Ramsey LB. Pharmacogenomics of acute lymphoid leukemia: new insights into treatment toxicity and efficacy. Hematology Am Soc Hematol Educ Program. 2013;2013(1):126–130. doi:10.1182/asheducation-2013.1.12624319173
   PubMed Web of Science ®Google Scholar
• Zaza G, Cheok M, Krynetskaia N, et al. Thiopurine pathway. Pharmacogenet Genomics. 2010;20(9):573–574. doi:10.1097/FPC.0b013e328334338f19952870
   PubMed Web of Science ®Google Scholar
• Mikkelsen TS, Thorn CF, Yang JJ, et al. PharmGKB summary: methotrexate pathway. Pharmacogenet Genomics. 2011;21(10):679–686. doi:10.1097/FPC.0b013e328343dd9321317831
   PubMed Web of Science ®Google Scholar
• Gregers J, Green H, Christensen IJ, et al. Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2015;15(4):372–379. doi:10.1038/tpj.2014.8125582575
   PubMed Web of Science ®Google Scholar
• Zgheib NK, Akra-Ismail M, Aridi C, et al. Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia. Pharmacogenet Genomics. 2014;24(8):387–396. doi:10.1097/FPC.000000000000006925007187
   PubMed Web of Science ®Google Scholar
• ElFayoumi RI, Hagras MM, Abozenadaha A, et al. The influence of polymorphisms in the drug transporter, ABCB1 on the toxicity of glucocorticoids in Saudi children with acute lymphoblastic leukaemia. Pharmacol Rep. 2019;71(1):90–95. doi:10.1016/j.pharep.2018.09.01030508724
   PubMed Web of Science ®Google Scholar
• Liu Y, Yin Y, Sheng Q, et al. Association of ABCC2-24C>T polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemia. PLoS One. 2014;9(1):e82681. doi:10.1371/journal.pone.008268124404132
   PubMed Web of Science ®Google Scholar
• Hareedy MS, El Desoky ES, Woillard JB, et al. Genetic variants in 6-mercaptopurine pathway as potential factors of hematological toxicity in acute lymphoblastic leukemia patients. Pharmacogenomics. 2015;16(10):1119–1134. doi:10.2217/PGS.15.6226237184
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Nakadate H, Kondoh K, Nakamura K, Koh K, Manabe A. Interaction between NUDT15 and ABCC4 variants enhances intolerability of 6-mercaptopurine in Japanese patients with childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2018;18(2):275–280. doi:10.1038/tpj.2017.1228418010
   PubMed Web of Science ®Google Scholar
• Gregers J, Christensen IJ, Dalhoff K, et al. The association of reduced folate carrier 80G>A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number. Blood. 2010;115(23):4671–4677. doi:10.1182/blood-2010-01-25695820335220
   PubMed Web of Science ®Google Scholar
• Eldem I, Yavuz D, Cumaogullari O, et al. SLCO1B1 Polymorphisms are Associated With Drug Intolerance in Childhood Leukemia Maintenance Therapy. J Pediatr Hematol Oncol. 2018;40(5):e289–e294. doi:10.1097/MPH.000000000000115329683944
   PubMed Web of Science ®Google Scholar
• Marino S, Verzegnassi F, Tamaro P, et al. Response to glucocorticoids and toxicity in childhood acute lymphoblastic leukemia: role of polymorphisms of genes involved in glucocorticoid response. Pediatr Blood Cancer. 2009;53(6):984–991. doi:10.1002/pbc.2216319621425
   PubMed Web of Science ®Google Scholar
• Smid A, Karas-Kuzelicki N, Jazbec J, Mlinaric-Rascan I. PACSIN2 polymorphism is associated with thiopurine-induced hematological toxicity in children with acute lymphoblastic leukaemia undergoing maintenance therapy. Sci Rep. 2016;6(1):30244. doi:10.1038/srep3024427452984
   PubMed Web of Science ®Google Scholar
• Lennard L, Cartwright CS, Wade R, Vora A. Thiopurine dose intensity and treatment outcome in childhood lymphoblastic leukaemia: the influence of thiopurine methyltransferase pharmacogenetics. Br J Haematol. 2015;169(2):228–240. doi:10.1111/bjh.1324025441457
   PubMed Web of Science ®Google Scholar
• Milosevic G, Kotur N, Krstovski N, et al. Variants in TPMT, ITPA, ABCC4 and ABCB1 Genes As Predictors of 6-mercaptopurine Induced Toxicity in Children with Acute Lymphoblastic Leukemia. J Med Biochem. 2018;37(3):320–327. doi:10.1515/jomb-2017-006030598629
   PubMed Web of Science ®Google Scholar
• Albayrak M, Konyssova U, Kaya Z, et al. Thiopurine methyltransferase polymorphisms and mercaptopurine tolerance in Turkish children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2011;68(5):1155–1159. doi:10.1007/s00280-011-1599-721400026
   PubMed Web of Science ®Google Scholar
• Tumer TB, Ulusoy G, Adali O, Sahin G, Gozdasoglu S, Arinc E. The low frequency of defective TPMT alleles in Turkish population: a study on pediatric patients with acute lymphoblastic leukemia. Am J Hematol. 2007;82(10):906–910. doi:10.1002/ajh.2094717617792
   PubMed Web of Science ®Google Scholar
• Peregud-Pogorzelski J, Tetera-Rudnicka E, Kurzawski M, et al. Thiopurine S-methyltransferase (TPMT) polymorphisms in children with acute lymphoblastic leukemia, and the need for reduction or cessation of 6-mercaptopurine doses during maintenance therapy: the Polish multicenter analysis. Pediatr Blood Cancer. 2011;57(4):578–582. doi:10.1002/pbc.2301321319286
   PubMed Web of Science ®Google Scholar
• Liang DC, Yang CP, Liu HC, et al. NUDT15 gene polymorphism related to mercaptopurine intolerance in Taiwan Chinese children with acute lymphoblastic leukemia. Pharmacogenomics J. 2016;16(6):536–539. doi:10.1038/tpj.2015.7526503813
   PubMed Web of Science ®Google Scholar
• Soler AM, Olano N, Mendez Y, et al. TPMT and NUDT15 genes are both related to mercaptopurine intolerance in acute lymphoblastic leukaemia patients from Uruguay. Br J Haematol. 2018;181(2):252–255.28146264
   PubMed Web of Science ®Google Scholar
• Moriyama T, Nishii R, Perez-Andreu V, et al. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet. 2016;48(4):367–373. doi:10.1038/ng.350826878724
   PubMed Web of Science ®Google Scholar
• Yang JJ, Landier W, Yang W, et al. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J Clin Oncol. 2015;33(11):1235–1242. doi:10.1200/JCO.2014.59.467125624441
   PubMed Web of Science ®Google Scholar
• Zhou H, Li L, Yang P, et al. Optimal predictor for 6-mercaptopurine intolerance in Chinese children with acute lymphoblastic leukemia: NUDT15, TPMT, or ITPA genetic variants? BMC Cancer. 2018;18(1):516. doi:10.1186/s12885-018-4398-229720126
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Kato M, Hasegawa D, et al. Susceptibility to 6-MP toxicity conferred by a NUDT15 variant in Japanese children with acute lymphoblastic leukaemia. Br J Haematol. 2015;171(1):109–115. doi:10.1111/bjh.1351826033531
   PubMed Web of Science ®Google Scholar
• Chiengthong K, Ittiwut C, Muensri S, et al. NUDT15 c.415C>T increases risk of 6-mercaptopurine induced myelosuppression during maintenance therapy in children with acute lymphoblastic leukemia. Haematologica. 2016;101(1):e24–26. doi:10.3324/haematol.2015.13477526405151
   PubMed Web of Science ®Google Scholar
• Hawwa AF, Millership JS, Collier PS, et al. Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine. Br J Clin Pharmacol. 2008;66(4):517–528. doi:10.1111/j.1365-2125.2008.03248.x18662289
   PubMed Web of Science ®Google Scholar
• Khera S, Trehan A, Bhatia P, Singh M, Bansal D, Varma N. Prevalence of TPMT, ITPA and NUDT 15 genetic polymorphisms and their relation to 6MP toxicity in north Indian children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2019;83(2):341–348. doi:10.1007/s00280-018-3732-330474703
   PubMed Web of Science ®Google Scholar
• Moradveisi B, Muwakkit S, Zamani F, Ghaderi E, Mohammadi E, Zgheib NK. ITPA, TPMT, and NUDT15 Genetic Polymorphisms Predict 6-Mercaptopurine Toxicity in Middle Eastern Children With Acute Lymphoblastic Leukemia. Front Pharmacol. 2019;10:916. doi:10.3389/fphar.2019.0091631507415
   PubMed Web of Science ®Google Scholar
• Stocco G, Cheok MH, Crews KR, et al. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther. 2009;85(2):164–172. doi:10.1038/clpt.2008.15418685564
   PubMed Web of Science ®Google Scholar
• Huang L, Tissing WJ, de Jonge R, van Zelst BD, Pieters R. Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia. Leukemia. 2008;22(9):1798–1800. doi:10.1038/leu.2008.6618368069
   PubMed Web of Science ®Google Scholar
• Araoz HV, D’Aloi K, Foncuberta ME, et al. Pharmacogenetic studies in children with acute lymphoblastic leukemia in Argentina. Leuk Lymphoma. 2015;56(5):1370–1378. doi:10.3109/10428194.2014.95184425110820
   PubMed Web of Science ®Google Scholar
• Chiusolo P, Reddiconto G, Casorelli I, et al. Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann Oncol. 2002;13(12):1915–1918. doi:10.1093/annonc/mdf32212453860
   PubMed Web of Science ®Google Scholar
• Shimasaki N, Mori T, Torii C, et al. Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol. 2008;30(5):347–352. doi:10.1097/MPH.0b013e318165b25d18458567
   PubMed Web of Science ®Google Scholar
• Kantar M, Kosova B, Cetingul N, et al. Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Leuk Lymphoma. 2009;50(6):912–917. doi:10.1080/1042819090289381919391036
   PubMed Web of Science ®Google Scholar
• Kodidela S, Pradhan SC, Dubashi B, Basu D. Influence of dihydrofolate reductase gene polymorphisms rs408626 (−317A>G) and rs442767 (−680C>A) on the outcome of methotrexate-based maintenance therapy in South Indian patients with acute lymphoblastic leukemia. Eur J Clin Pharmacol. 2015;71(11):1349–1358. doi:10.1007/s00228-015-1930-z26335211
   PubMed Web of Science ®Google Scholar
• Salazar J, Altes A, Del Rio E, et al. Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia. Pharmacogenomics J. 2012;12(5):379–385. doi:10.1038/tpj.2011.2521747412
   PubMed Web of Science ®Google Scholar
• Wang Q, He G, Hou M, et al. Cell Cycle Regulation by Alternative Polyadenylation of CCND1. Sci Rep. 2018;8(1):6824. doi:10.1038/s41598-018-25141-029717174
   PubMed Web of Science ®Google Scholar
• Costea I, Moghrabi A, Laverdiere C, Graziani A, Krajinovic M. Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia. Haematologica. 2006;91(8):1113–1116.16870553
   PubMed Web of Science ®Google Scholar
• Garcia-Bournissen F, Moghrabi A, Krajinovic M. Therapeutic responses in childhood acute lymphoblastic leukemia (ALL) and haplotypes of gamma glutamyl hydrolase (GGH) gene. Leuk Res. 2007;31(7):1023–1025. doi:10.1016/j.leukres.2006.08.00716999998
   PubMed Web of Science ®Google Scholar
• Csordas K, Lautner-Csorba O, Semsei AF, et al. Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia. Br J Haematol. 2014;166(3):410–420. doi:10.1111/bjh.1288624712521
   PubMed Web of Science ®Google Scholar
• Oosterom N, Berrevoets M, den Hoed MAH, et al. The role of genetic polymorphisms in the thymidylate synthase (TYMS) gene in methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia. Pharmacogenet Genomics. 2018;28(10):223–229. doi:10.1097/FPC.000000000000035230222710
   PubMed Web of Science ®Google Scholar
• Trevino LR, Shimasaki N, Yang W, et al. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol. 2009;27(35):5972–5978. doi:10.1200/JCO.2008.20.415619901119
   PubMed Web of Science ®Google Scholar
• Lopez-Lopez E, Ballesteros J, Pinan MA, et al. Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia. Pharmacogenet Genomics. 2013;23(2):53–61. doi:10.1097/FPC.0b013e32835c3b2423222202
   PubMedGoogle Scholar
• den Hoed MA, Lopez-Lopez E, Te Winkel ML, et al. Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia. Pharmacogenomics J. 2015;15(3):248–254. doi:10.1038/tpj.2014.6325348617
   PubMed Web of Science ®Google Scholar
• Roy Moulik N, Kumar A, Agrawal S, Awasthi S, Mahdi AA, Kumar A. Role of folate status and methylenetetrahydrofolate reductase genotype on the toxicity and outcome of induction chemotherapy in children with acute lymphoblastic leukemia. Leuk Lymphoma. 2015;56(5):1379–1384. doi:10.3109/10428194.2014.94760825065700
   PubMed Web of Science ®Google Scholar
• Hunger SP, Loh ML, Whitlock JA, et al. Children’s Oncology Group’s 2013 blueprint for research: acute lymphoblastic leukemia. Pediatr Blood Cancer. 2013;60(6):957–963. doi:10.1002/pbc.2442023255467
   PubMed Web of Science ®Google Scholar
• Gutierrez-Camino A, Martin-Guerrero I, Garcia-Orad A. PNPLA3 rs738409 and Hepatotoxicity in Children With B-cell Acute Lymphoblastic Leukemia: A Validation Study in a Spanish Cohort. Clin Pharmacol Ther. 2017;102(6):906. doi:10.1002/cpt.75628744905
   PubMed Web of Science ®Google Scholar
• Kienesberger PC, Oberer M, Lass A, Zechner R. Mammalian patatin domain containing proteins: a family with diverse lipolytic activities involved in multiple biological functions. J Lipid Res. 2009;50(Suppl):S63–68. doi:10.1194/jlr.R800082-JLR20019029121
   PubMed Web of Science ®Google Scholar
• Liu Y, Fernandez CA, Smith C, et al. Genome-Wide Study Links PNPLA3 Variant With Elevated Hepatic Transaminase After Acute Lymphoblastic Leukemia Therapy. Clin Pharmacol Ther. 2017;102(1):131–140. doi:10.1002/cpt.62928090653
   PubMed Web of Science ®Google Scholar
• Smagris E, BasuRay S, Li J, et al. Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology. 2015;61(1):108–118. doi:10.1002/hep.2724224917523
   PubMed Web of Science ®Google Scholar
• Qiu Q, Huang J, Lin Y, et al. Polymorphisms and pharmacogenomics for the toxicity of methotrexate monotherapy in patients with rheumatoid arthritis: A systematic review and meta-analysis. Medicine. 2017;96(11):e6337. doi:10.1097/MD.000000000000633728296761
   PubMed Web of Science ®Google Scholar
• Ongaro A, De Mattei M, Della Porta MG, et al. Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival. Haematologica. 2009;94(10):1391–1398. doi:10.3324/haematol.2009.00832619648163
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Manabe A, Nakadate H, et al. Methylenetetrahydrofolate reductase gene haplotypes affect toxicity during maintenance therapy for childhood acute lymphoblastic leukemia in Japanese patients. Leuk Lymphoma. 2014;55(5):1126–1131. doi:10.3109/10428194.2013.82590223865834
   PubMed Web of Science ®Google Scholar
• Wan Rosalina WR, Teh LK, Mohamad N, et al. Polymorphism of ITPA 94C>A and risk of adverse effects among patients with acute lymphoblastic leukaemia treated with 6-mercaptopurine. J Clin Pharm Ther. 2012;37(2):237–241. doi:10.1111/j.1365-2710.2011.01272.x21545474
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol. 2012;82(1):51–77. doi:10.1016/j.critrevonc.2011.04.01221908200
   PubMed Web of Science ®Google Scholar
• Abaji R, Ceppi F, Patel S, et al. Genetic risk factors for VIPN in childhood acute lymphoblastic leukemia patients identified using whole-exome sequencing. Pharmacogenomics. 2018;19(15):1181–1193. doi:10.2217/pgs-2018-009330191766
   PubMed Web of Science ®Google Scholar
• Warren DT, Zhang Q, Weissberg PL, Shanahan CM. Nesprins: intracellular scaffolds that maintain cell architecture and coordinate cell function? Expert Rev Mol Med. 2005;7(11):1–15. doi:10.1017/S1462399405009294
   Google Scholar
• Mross C, Marko M, Munck M, et al. Depletion of Nesprin-2 is associated with an embryonic lethal phenotype in mice. Nucleus. 2018;9(1):503–515. doi:10.1080/19491034.2018.152366430220251
   PubMed Web of Science ®Google Scholar
• Kenmochi N, Suzuki T, Uechi T, et al. The human mitochondrial ribosomal protein genes: mapping of 54 genes to the chromosomes and implications for human disorders. Genomics. 2001;77(1–2):65–70. doi:10.1006/geno.2001.662211543634
   PubMed Web of Science ®Google Scholar
• Pavlovic S, Kotur N, Stankovic B, Zukic B, Gasic V, Dokmanovic L. Pharmacogenomic and Pharmacotranscriptomic Profiling of Childhood Acute Lymphoblastic Leukemia: paving the Way to Personalized Treatment. Genes. 2019;10(3):3. doi:10.3390/genes10030191
   Web of Science ®Google Scholar
• Ceppi F, Langlois-Pelletier C, Gagne V, et al. Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia. Pharmacogenomics. 2014;15(8):1105–1116. doi:10.2217/pgs.14.6825084203
   PubMed Web of Science ®Google Scholar
• Verrills NM, Liem NL, Liaw TY, Hood BD, Lock RB, Kavallaris M. Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia–an in vivo study. Proteomics. 2006;6(5):1681–1694. doi:10.1002/pmic.20050041716456880
   PubMed Web of Science ®Google Scholar
• Lopez-Lopez E, Gutierrez-Camino A, Astigarraga I, et al. Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia. Pharmacogenomics. 2016;17(7):731–741. doi:10.2217/pgs-2016-000127180762
   PubMed Web of Science ®Google Scholar
• Diouf B, Crews KR, Lew G, et al. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA. 2015;313(8):815–823. doi:10.1001/jama.2015.089425710658
   PubMed Web of Science ®Google Scholar
• Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4(4):253–265. doi:10.1038/nrc131715057285
   PubMed Web of Science ®Google Scholar
• Dennison JB, Kulanthaivel P, Barbuch RJ, Renbarger JL, Ehlhardt WJ, Hall SD. Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos. 2006;34(8):1317–1327. doi:10.1124/dmd.106.00990216679390
   PubMed Web of Science ®Google Scholar
• Egbelakin A, Ferguson MJ, MacGill EA, et al. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011;56(3):361–367. doi:10.1002/pbc.2284521225912
   PubMed Web of Science ®Google Scholar
• Li L, Sajdyk T, Smith EML, et al. Genetic Variants Associated With Vincristine-Induced Peripheral Neuropathy in Two Populations of Children With Acute Lymphoblastic Leukemia. Clin Pharmacol Ther. 2019;105(6):1421–1428. doi:10.1002/cpt.132430506673
   PubMed Web of Science ®Google Scholar
• Robertson NG, Cremers CW, Huygen PL, et al. Cochlin immunostaining of inner ear pathologic deposits and proteomic analysis in DFNA9 deafness and vestibular dysfunction. Hum Mol Genet. 2006;15(7):1071–1085. doi:10.1093/hmg/ddl02216481359
   PubMed Web of Science ®Google Scholar
• Zhang J, Fei T, Li Z, et al. BMP induces cochlin expression to facilitate self-renewal and suppress neural differentiation of mouse embryonic stem cells. J Biol Chem. 2013;288(12):8053–8060. doi:10.1074/jbc.M112.43399523344953
   PubMed Web of Science ®Google Scholar
• Bond AM, Bhalala OG, Kessler JA. The dynamic role of bone morphogenetic proteins in neural stem cell fate and maturation. Dev Neurobiol. 2012;72(7):1068–1084. doi:10.1002/dneu.2202222489086
   PubMed Web of Science ®Google Scholar
• Mont MA, Hungerford DS. Non-traumatic avascular necrosis of the femoral head. J Bone Joint Surg Am. 1995;77(3):459–474. doi:10.2106/00004623-199503000-000187890797
   PubMed Web of Science ®Google Scholar
• Janke LJ, Liu C, Vogel P, et al. Primary epiphyseal arteriopathy in a mouse model of steroid-induced osteonecrosis. Am J Pathol. 2013;183(1):19–25. doi:10.1016/j.ajpath.2013.03.00423673001
   PubMed Web of Science ®Google Scholar
• French D, Hamilton LH, Mattano LA, et al. A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Blood. 2008;111(9):4496–4499. doi:10.1182/blood-2007-11-12388518285546
   PubMed Web of Science ®Google Scholar
• Kawedia JD, Kaste SC, Pei D, et al. Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood. 2011;117(8):2340–2347. doi:10.1182/blood-2010-10-31196921148812
   PubMed Web of Science ®Google Scholar
• Karol SE, Yang W, Van Driest SL, et al. Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia. Blood. 2015;126(15):1770–1776. doi:10.1182/blood-2015-05-64360126265699
   PubMed Web of Science ®Google Scholar
• Karol SE, Mattano LA, Yang W, et al. Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia. Blood. 2016;127(5):558–564. doi:10.1182/blood-2015-10-67384826590194
   PubMed Web of Science ®Google Scholar
• Maurer T, Zimmermann G, Maurer S, Stegmaier S, Wagner C, Hansch GM. Inhibition of osteoclast generation: a novel function of the bone morphogenetic protein 7/osteogenic protein 1. Mediators Inflamm. 2012;2012:171209. doi:10.1155/2012/17120923132958
   PubMed Web of Science ®Google Scholar
• Zhang S, Fantozzi I, Tigno DD, et al. Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2003;285(3):L740–754. doi:10.1152/ajplung.00284.200212740218
   PubMed Web of Science ®Google Scholar
• Ramsey LB, Pounds S, Cheng C, et al. Genetics of pleiotropic effects of dexamethasone. Pharmacogenet Genomics. 2017;27(8):294–302. doi:10.1097/FPC.000000000000029328628558
   PubMed Web of Science ®Google Scholar
• Relling MV, Yang W, Das S, et al. Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J Clin Oncol. 2004;22(19):3930–3936. doi:10.1200/JCO.2004.11.02015459215
   PubMed Web of Science ®Google Scholar
• Munker R, Hill U, Jehn U, Kolb HJ, Schalhorn A. Renal complications in acute leukemias. Haematologica. 1998;83(5):416–421.9658725
   PubMed Web of Science ®Google Scholar
• Liu C, Yang W, Devidas M, et al. Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia. J Clin Oncol. 2016;34(18):2133–2140. doi:10.1200/JCO.2015.64.581227114598
   PubMed Web of Science ®Google Scholar
• Catasus L, Vendrell J, Aviles FX, Carreira S, Puigserver A, Billeter M. The sequence and conformation of human pancreatic procarboxypeptidase A2. cDNA cloning, sequence analysis, and three-dimensional model. J Biol Chem. 1995;270(12):6651–6657. doi:10.1074/jbc.270.12.66517896805
   PubMed Web of Science ®Google Scholar
• Abaji R, Gagne V, Xu CJ, et al. Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients. Oncotarget. 2017;8(27):43752–43767. doi:10.18632/oncotarget.1795928574850
   PubMedGoogle Scholar
• Cai L, Deng SL, Liang L, et al. Identification of genetic associations of SP110/MYBBP1A/RELA with pulmonary tuberculosis in the Chinese Han population. Hum Genet. 2013;132(3):265–273. doi:10.1007/s00439-012-1244-523129390
   PubMed Web of Science ®Google Scholar
• Rakonczay Z, Hegyi P, Takacs T, McCarroll J, Saluja AK. The role of NF-kappaB activation in the pathogenesis of acute pancreatitis. Gut. 2008;57(2):259–267. doi:10.1136/gut.2007.12411517675325
   PubMed Web of Science ®Google Scholar
• Killander D, Dohlwitz A, Engstedt L, et al. Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia. Cancer. 1976;37(1):220–228. doi:10.1002/1097-0142(197601)37:1<220::aid-cncr2820370132>3.0.co;2-w1061636
   PubMed Web of Science ®Google Scholar
• Fernandez CA, Stewart E, Panetta JC, et al. Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase. Cancer Chemother Pharmacol. 2014;73(6):1307–1313. doi:10.1007/s00280-014-2464-224771103
   PubMed Web of Science ®Google Scholar
• Kerner B, Jasinska AJ, DeYoung J, Almonte M, Choi OW, Freimer NB. Polymorphisms in the GRIA1 gene region in psychotic bipolar disorder. Am J Med Genet B Neuropsychiatr Genet. 2009;150B(1):24–32. doi:10.1002/ajmg.b.3078018484081
   PubMed Web of Science ®Google Scholar
• Chen SH, Pei D, Yang W, et al. Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity. Clin Pharmacol Ther. 2010;88(2):191–196. doi:10.1038/clpt.2010.9420592726
   PubMed Web of Science ®Google Scholar
• Fernandez CA, Smith C, Yang W, et al. Genome-wide analysis links NFATC2 with asparaginase hypersensitivity. Blood. 2015;126(1):69–75. doi:10.1182/blood-2015-02-62880025987655
   PubMed Web of Science ®Google Scholar
• Kutszegi N, Yang X, Gezsi A, et al. HLA-DRB1*07:01-HLA-DQA1*02:01-HLA-DQB1*02:02 haplotype is associated with a high risk of asparaginase hypersensitivity in acute lymphoblastic leukemia. Haematologica. 2017;102(9):1578–1586. doi:10.3324/haematol.2017.16821128596278
   PubMed Web of Science ®Google Scholar
• Yokoi T, Nakajima M. microRNAs as mediators of drug toxicity. Annu Rev Pharmacol Toxicol. 2013;53(1):377–400. doi:10.1146/annurev-pharmtox-011112-14025023189953
   PubMed Web of Science ®Google Scholar
• Lopez-Lopez E, Gutierrez-Camino A, Pinan MA, et al. Pharmacogenetics of microRNAs and microRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia. PLoS One. 2014;9(3):e91261. doi:10.1371/journal.pone.009126124614921
   PubMed Web of Science ®Google Scholar
• Gutierrez-Camino A, Oosterom N, den Hoed MAH, et al. The miR-1206 microRNA variant is associated with methotrexate-induced oral mucositis in pediatric acute lymphoblastic leukemia. Pharmacogenet Genomics. 2017;27(8):303–306. doi:10.1097/FPC.000000000000029128628559
   PubMed Web of Science ®Google Scholar
• Gutierrez-Camino A, Umerez M, Lopez-Lopez E, et al. Involvement of miRNA polymorphism in mucositis development in childhood acute lymphoblastic leukemia treatment. Pharmacogenomics. 2018;19(18):1403–1412. doi:10.2217/pgs-2018-011330479191
   PubMed Web of Science ®Google Scholar
• Gutierrez-Camino A, Umerez M, Martin-Guerrero I, et al. Mir-pharmacogenetics of Vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia. Pharmacogenomics J. 2018;18(6):704–712. doi:10.1038/s41397-017-0003-329282364
   PubMed Web of Science ®Google Scholar
• Iparraguirre L, Gutierrez-Camino A, Umerez M, et al. MiR-pharmacogenetics of methotrexate in childhood B-cell acute lymphoblastic leukemia. Pharmacogenet Genomics. 2016;26(11):517–525. doi:10.1097/FPC.000000000000024527649261
   PubMed Web of Science ®Google Scholar
• Zgheib NK, Akika R, Mahfouz R, et al. NUDT15 and TPMT genetic polymorphisms are related to 6-mercaptopurine intolerance in children treated for acute lymphoblastic leukemia at the Children’s Cancer Center of Lebanon. Pediatr Blood Cancer. 2017;64(1):146–150. doi:10.1002/pbc.2618927577869
   PubMed Web of Science ®Google Scholar
• Kim HT, Choi R, Won HH, et al. NUDT15 genotype distributions in the Korean population. Pharmacogenet Genomics. 2017;27(5):197–200. doi:10.1097/FPC.000000000000027428277331
   PubMed Web of Science ®Google Scholar
• Yang JJ, Cheng C, Yang W, et al. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA. 2009;301(4):393–403. doi:10.1001/jama.2009.719176441
   PubMed Web of Science ®Google Scholar
• Stanulla M, Schaeffeler E, Flohr T, et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA. 2005;293(12):1485–1489. doi:10.1001/jama.293.12.148515784872
   PubMed Web of Science ®Google Scholar
• Perez-Andreu V, Roberts KG, Harvey RC, et al. Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nat Genet. 2013;45(12):1494–1498. doi:10.1038/ng.280324141364
   PubMed Web of Science ®Google Scholar
• Aplenc R, Thompson J, Han P, et al. Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res. 2005;65(6):2482–2487. doi:10.1158/0008-5472.CAN-04-260615781665
   PubMed Web of Science ®Google Scholar
• D’Angelo V, Ramaglia M, Iannotta A, et al. Methotrexate toxicity and efficacy during the consolidation phase in paediatric acute lymphoblastic leukaemia and MTHFR polymorphisms as pharmacogenetic determinants. Cancer Chemother Pharmacol. 2011;68(5):1339–1346. doi:10.1007/s00280-011-1665-121590445
   PubMed Web of Science ®Google Scholar
• El-Khodary NM, El-Haggar SM, Eid MA, Ebeid EN. Study of the pharmacokinetic and pharmacogenetic contribution to the toxicity of high-dose methotrexate in children with acute lymphoblastic leukemia. Med Oncol. 2012;29(3):2053–2062. doi:10.1007/s12032-011-9997-621644011
   PubMed Web of Science ®Google Scholar
• Takanashi M, Morimoto A, Yagi T, et al. Impact of glutathione S-transferase gene deletion on early relapse in childhood B-precursor acute lymphoblastic leukemia. Haematologica. 2003;88(11):1238–1244.14607752
   PubMed Web of Science ®Google Scholar
• Leonardi DB, Abbate M, Riccheri MC, et al. Improving risk stratification of patients with childhood acute lymphoblastic leukemia: glutathione-S-Transferases polymorphisms are associated with increased risk of relapse. Oncotarget. 2017;8(1):110–117. doi:10.18632/oncotarget.860627058755
   PubMedGoogle Scholar
• Yang JJ, Cheng C, Devidas M, et al. Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood. 2012;120(20):4197–4204. doi:10.1182/blood-2012-07-44010723007406
   PubMed Web of Science ®Google Scholar
• Lauten M, Matthias T, Stanulla M, Beger C, Welte K, Schrappe M. Association of initial response to prednisone treatment in childhood acute lymphoblastic leukaemia and polymorphisms within the tumour necrosis factor and the interleukin-10 genes. Leukemia. 2002;16(8):1437–1442. doi:10.1038/sj.leu.240254512145682
   PubMed Web of Science ®Google Scholar
• Rocha JC, Cheng C, Liu W, et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood. 2005;105(12):4752–4758. doi:10.1182/blood-2004-11-454415713801
   PubMed Web of Science ®Google Scholar
• Schmiegelow K, Forestier E, Kristinsson J, et al. Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Leukemia. 2009;23(3):557–564. doi:10.1038/leu.2008.31618987654
   PubMed Web of Science ®Google Scholar
• Relling MV, Pui CH, Cheng C, Evans WE. Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood. 2006;107(2):843–844. doi:10.1182/blood-2005-08-337916401827
   PubMed Web of Science ®Google Scholar
• Zhai X, Wang H, Zhu X, et al. Gene polymorphisms of ABC transporters are associated with clinical outcomes in children with acute lymphoblastic leukemia. Arch Med Sci. 2012;8(4):659–671. doi:10.5114/aoms.2012.3029023056078
   PubMed Web of Science ®Google Scholar
• Costea I, Moghrabi A, Krajinovic M. The influence of cyclin D1 (CCND1) 870A>G polymorphism and CCND1-thymidylate synthase (TS) gene-gene interaction on the outcome of childhood acute lymphoblastic leukaemia. Pharmacogenetics. 2003;13(9):577–580. doi:10.1097/00008571-200309000-0000612972956
   PubMedGoogle Scholar
• Krajinovic M, Labuda D, Mathonnet G, et al. Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia. Clin Cancer Res. 2002;8(3):802–810.11895912
   PubMed Web of Science ®Google Scholar
• Database of Single Nucleotide Polymorphisms (dbSNP). Available from: https://www.ncbi.nlm.nih.gov/snp/. Accessed 7 21, 2020.
   Google Scholar
• Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354(2):166–178. doi:10.1056/NEJMra05260316407512
   PubMed Web of Science ®Google Scholar
• Cheok MH, Evans WE. Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat Rev Cancer. 2006;6(2):117–129. doi:10.1038/nrc180016491071
   PubMed Web of Science ®Google Scholar
• Tinhofer I, Marschitz I, Henn T, Egle A, Greil R. Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. Blood. 2000;95(2):610–618. doi:10.1182/blood.V95.2.61010627470
   PubMed Web of Science ®Google Scholar
• Cario G, Izraeli S, Teichert A, et al. High interleukin-15 expression characterizes childhood acute lymphoblastic leukemia with involvement of the CNS. J Clin Oncol. 2007;25(30):4813–4820. doi:10.1200/JCO.2007.11.816617947730
   PubMed Web of Science ®Google Scholar
• Zaza G, Cheok M, Yang W, et al. Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. Blood. 2005;106(5):1778–1785. doi:10.1182/blood-2005-01-014315905191
   PubMed Web of Science ®Google Scholar
• Heim S, Lage H. Transcriptome analysis of different multidrug-resistant gastric carcinoma cells. In Vivo. 2005;19(3):583–590.15875780
   PubMed Web of Science ®Google Scholar
• Kim H, Kang HJ, Kim HJ, et al. Pharmacogenetic analysis of pediatric patients with acute lymphoblastic leukemia: a possible association between survival rate and ITPA polymorphism. PLoS One. 2012;7(9):e45558. doi:10.1371/journal.pone.004555823029095
   PubMed Web of Science ®Google Scholar
• Fujiwara T, O’Geen H, Keles S, et al. Discovering hematopoietic mechanisms through genome-wide analysis of GATA factor chromatin occupancy. Mol Cell. 2009;36(4):667–681. doi:10.1016/j.molcel.2009.11.00119941826
   PubMed Web of Science ®Google Scholar
• Jeha S, Pei D, Choi J, et al. Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: st Jude Total Therapy Study 16. J Clin Oncol. 2019;37(35):3377–3391. doi:10.1200/JCO.19.0169231657981
   PubMed Web of Science ®Google Scholar
• Gaudichon J, Jakobczyk H, Debaize L, et al. Mechanisms of extramedullary relapse in acute lymphoblastic leukemia: reconciling biological concepts and clinical issues. Blood Rev. 2019;36:40–56. doi:10.1016/j.blre.2019.04.00331010660
   PubMed Web of Science ®Google Scholar
• Thummel KE, Brimer C, Yasuda K, et al. Transcriptional control of intestinal cytochrome P-4503A by 1alpha,25-dihydroxy vitamin D3. Mol Pharmacol. 2001;60(6):1399–1406. doi:10.1124/mol.60.6.139911723248
   PubMed Web of Science ®Google Scholar
• Kunkele A, Grosse-Lordemann A, Schramm A, Eggert A, Schulte JH, Bachmann HS. The BCL2-938 C > A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia. BMC Cancer. 2013;13:452. doi:10.1186/1471-2407-13-45224088574
   PubMed Web of Science ®Google Scholar
• McDonagh EM, Whirl-Carrillo M, Garten Y, Altman RB, Klein TE. From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. Biomark Med. 2011;5(6):795–806. doi:10.2217/bmm.11.9422103613
   PubMed Web of Science ®Google Scholar
• Whirl-Carrillo M, McDonagh EM, Hebert JM, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92(4):414–417. doi:10.1038/clpt.2012.9622992668
   PubMed Web of Science ®Google Scholar
• Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980;32(5):651–662.7191632
   PubMed Web of Science ®Google Scholar
• Andersen JB, Szumlanski C, Weinshilboum RM, Schmiegelow K. Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency. Acta Paediatr. 1998;87(1):108–111. doi:10.1080/080352598501580019510461
   PubMed Web of Science ®Google Scholar
• Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr. 1991;119(6):985–989. doi:10.1016/S0022-3476(05)83063-X1960624
   PubMed Web of Science ®Google Scholar
• Krynetski EY, Schuetz JD, Galpin AJ, Pui CH, Relling MV, Evans WE. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci U S A. 1995;92(4):949–953. doi:10.1073/pnas.92.4.9497862671
   PubMed Web of Science ®Google Scholar
• Lennard L, Gibson BE, Nicole T, Lilleyman JS. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child. 1993;69(5):577–579. doi:10.1136/adc.69.5.5778257179
   PubMed Web of Science ®Google Scholar
• Otterness DM, Szumlanski CL, Wood TC, Weinshilboum RM. Human thiopurine methyltransferase pharmacogenetics. Kindred with a terminal exon splice junction mutation that results in loss of activity. J Clin Invest. 1998;101(5):1036–1044. doi:10.1172/JCI10049486974
   PubMed Web of Science ®Google Scholar
• Higgs JE, Payne K, Roberts C, Newman WG. Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? Pharmacogenomics. 2010;11(2):177–188. doi:10.2217/pgs.09.15520136357
   PubMed Web of Science ®Google Scholar
• Relling MV, Gardner EE, Sandborn WJ, et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther. 2013;93(4):324–325. doi:10.1038/clpt.2013.423422873
   PubMed Web of Science ®Google Scholar
• Adam de Beaumais T, Fakhoury M, Medard Y, et al. Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy. Br J Clin Pharmacol. 2011;71(4):575–584. doi:10.1111/j.1365-2125.2010.03867.x21395650
   PubMed Web of Science ®Google Scholar
• Adam de Beaumais T, Jacqz-Aigrain E. Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia. Eur J Clin Pharmacol. 2012;68(9):1233–1242. doi:10.1007/s00228-012-1251-422421815
   PubMed Web of Science ®Google Scholar
• Yang SK, Hong M, Baek J, et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet. 2014;46(9):1017–1020. doi:10.1038/ng.306025108385
   PubMed Web of Science ®Google Scholar
• Koutsilieri S, Caudle KE, Alzghari SK, Monte AA, Relling MV, Patrinos GP. Optimizing thiopurine dosing based on TPMT and NUDT15 genotypes: it takes two to tango. Am J Hematol. 2019;94(7):737–740. doi:10.1002/ajh.2548530945335
   PubMed Web of Science ®Google Scholar
• Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095–1105. doi:10.1002/cpt.130430447069
   PubMed Web of Science ®Google Scholar
• Cargnin S, Genazzani AA, Canonico PL, Terrazzino S. Diagnostic accuracy of NUDT15 gene variants for thiopurine-induced leukopenia: a systematic review and meta-analysis. Pharmacol Res. 2018;135:102–111. doi:10.1016/j.phrs.2018.07.02130048756
   PubMed Web of Science ®Google Scholar
• Moriyama T, Yang YL, Nishii R, et al. Novel variants in NUDT15 and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry. Blood. 2017;130(10):1209–1212. doi:10.1182/blood-2017-05-78238328659275
   PubMed Web of Science ®Google Scholar
• Yin D, Xia X, Zhang J, et al. Impact of NUDT15 polymorphisms on thiopurines-induced myelotoxicity and thiopurines tolerance dose. Oncotarget. 2017;8(8):13575–13585. doi:10.18632/oncotarget.1459428088792
   PubMedGoogle Scholar
• He HR, Chen SY, You HS, et al. Association between methylenetetrahydrofolate reductase polymorphisms and the relapse of acute lymphoblastic leukemia: a meta-analysis. Pharmacogenomics J. 2014;14(5):432–438. doi:10.1038/tpj.2014.1024637499
   PubMed Web of Science ®Google Scholar
• Zhu C, Liu YW, Wang SZ, et al. Associations between the C677T and A1298C polymorphisms of MTHFR and the toxicity of methotrexate in childhood malignancies: a meta-analysis. Pharmacogenomics J. 2018;18(3):450–459. doi:10.1038/tpj.2017.3428696419
   PubMed Web of Science ®Google Scholar
• Stock W, Diouf B, Crews KR, et al. An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia. Clin Pharmacol Ther. 2017;101(3):391–395. doi:10.1002/cpt.50627618250
   PubMed Web of Science ®Google Scholar
• Gutierrez-Camino A, Martin-Guerrero I, Lopez-Lopez E, et al. Lack of association of the CEP72 rs924607 TT genotype with vincristine-related peripheral neuropathy during the early phase of pediatric acute lymphoblastic leukemia treatment in a Spanish population. Pharmacogenet Genomics. 2016;26(2):100–102. doi:10.1097/FPC.000000000000019126618658
   PubMed Web of Science ®Google Scholar
• Zgheib NK, Ghanem KM, Tamim H, et al. Genetic polymorphisms in candidate genes are not associated with increased vincristine-related peripheral neuropathy in Arab children treated for acute childhood leukemia: a single institution study. Pharmacogenet Genomics. 2018;28(8):189–195. doi:10.1097/FPC.000000000000034530119132
   PubMed Web of Science ®Google Scholar
• Fernandez CA, Smith C, Yang W, et al. HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies. Blood. 2014;124(8):1266–1276. doi:10.1182/blood-2014-03-56374224970932
   PubMed Web of Science ®Google Scholar
• Abou Diwan E, Zeitoun RI, Abou Haidar L, Cascorbi I, Khoueiry Zgheib N. Implementation and obstacles of pharmacogenetics in clinical practice: an international survey. Br J Clin Pharmacol. 2019;85(9):2076–2088. doi:10.1111/bcp.1399931141189
   PubMed Web of Science ®Google Scholar
• Roden DM, Van Driest SL, Mosley JD, et al. Benefit of Preemptive Pharmacogenetic Information on Clinical Outcome. Clin Pharmacol Ther. 2018;103(5):787–794. doi:10.1002/cpt.103529377064
   PubMed Web of Science ®Google Scholar
• Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526(7573):343–350. doi:10.1038/nature1581726469045
   PubMed Web of Science ®Google Scholar
• Hoffman JM, Haidar CE, Wilkinson MR, et al. PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics. Am J Med Genet C Semin Med Genet. 2014;166C(1):45–55. doi:10.1002/ajmg.c.3139124619595
   PubMed Web of Science ®Google Scholar
• van der Wouden CH, Cambon-Thomsen A, Cecchin E, et al. Implementing Pharmacogenomics in Europe: design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium. Clin Pharmacol Ther. 2017;101(3):341–358. doi:10.1002/cpt.60228027596
   PubMed Web of Science ®Google Scholar
• Volpi S, Bult CJ, Chisholm RL, et al. Research Directions in the Clinical Implementation of Pharmacogenomics: an Overview of US Programs and Projects. Clin Pharmacol Ther. 2018;103(5):778–786. doi:10.1002/cpt.104829460415
   PubMed Web of Science ®Google Scholar